The document discusses Aspergillus, a genus of fungi that can cause both positive and negative impacts. Positively, some species are used in food production, composting, and to produce pharmaceuticals. However, certain species can cause invasive and allergic diseases in humans. Aspergillus fumigatus is a common cause of invasive infections in immunocompromised individuals, causing diseases ranging from acute to chronic. Early diagnosis and treatment are important for improving outcomes.
Highlights the significance of Aspergillus genus. It's harmful through diseases and mycotoxins, but also beneficial in food, pharmaceuticals, and research.
Illustrates the life cycle of Aspergillus, including the inhalation of spores leading to germination, hyphal growth, and pathogenicity.
Discusses ~180 Aspergillus species, noting 38 are pathogenic, and classifies types of aspergillosis based on severity and duration of infection.
Explains how immunosuppression (due to various health conditions) increases susceptibility to Aspergillus infections, including respiratory ailments.
Describes the interaction between Aspergillus and the host's immune system, showing a spectrum of aspergillosis incidence based on immune status.
Shows the changing rates of invasive aspergillosis and its impact on patients with different underlying conditions, emphasizing leukaemia patients.
Presents diagnostic challenges and incidence rates of invasive aspergillosis in various patient demographics, emphasizing the importance of timely diagnosis.
Examines the connection between Aspergillus and thrombosis, and how it leads to complications like bleeding.
Highlights the incidence of cerebral aspergillosis in immunocompromised patients, particularly in those with invasive disease.
Stresses the importance of early diagnosis of invasive aspergillosis, correlating treatment timing with mortality rates.
Discusses the efficacy of fungal media over bacteriological media for sputum cultures, highlighting a significant increase in yield.
Details Aspergillus antigen tests for diagnosis and surveillance, noting limitations due to false positives and negatives.
Analyzes survival outcomes based on infection sites when treated with amphotericin B, showing varying survival functions.
Explains characteristics of sub-acute invasive aspergillosis in less immunocompromised patients, detailing typical disease progression.
Describes chronic necrotizing pulmonary aspergillosis, highlighting its delayed recognition and link to underlying health conditions.
Classifies types of aspergillosis, detailing diagnostic criteria and distinguishing characteristics of each type affecting the airways.
Presents data on risks and comorbidities in patients with aspergillus tracheobronchitis, stressing its significance in both healthy and immunocompromised.
Discusses the role of Mannose Binding Lectin (MBL) mutations in susceptibility to chronic pulmonary aspergillosis, with genetic data related to risk.
Details diagnostic criteria for ABPA, highlighting key tests for asthma patients and discussing related surfactant protein genetics.
Introduces the concept of eosinophilic fungal rhinosinusitis, linking chronic sinus issues with airborne fungi and patient symptoms.
Explores links between Aspergillus and asthma, summarizing evidence from studies on fungal sensitization and its effects on asthma severity. Reports on the relationship between home mold presence and asthma symptoms, emphasizing environmental influences on respiratory health.
The extraordinary spectrumof diseases
caused by Aspergillus
David W. Denning
Wythenshawe Hospital
University of Manchester
2.
The genus Aspergillus- importance to humanity
on the negative side:
cause invasive and allergic disease
in humans and other animals:
A. fumigatus
cause plant and food spoilage and
produce mycotoxins:
A. flavus and A. parasiticus
www.aspergillus.man.ac.uk
3.
The genus Aspergillus- importance to humanity
on the positive side:
composting
well-established model organism in cell biology and genetics:
A. nidulans
food production:
enzymes and organic acids: A. niger
East Asian foods: A. oryzae and A. sojae
pharmaceuticals:
echinocandins: A. nidulans and A. sydowi
lovastatin: A. terreus
fumagillin: A. fumigatus
www.aspergillus.man.ac.uk
The genus Aspergillus– ~180 species,
38 have caused disease (able to grow at 37C)
Common in the environment
Aspergillus
A. nidulans – may be amphotericin B resistant fumigatus
conidial head
A. niger A. flavus -sometimes to AmB of azole resistance
A. fumigatus low frequency
A. terreus – resistant amphotericin B resistant
www.aspergillus.man.ac.uk
6.
CLASSIFICATION OF ASPERGILLOSIS
Invasive aspergillosis
• Acute (<1 month course)
Airways/nasal • Subacute/chronic necrotising (1-3 months)
exposure to
airborne Chronic aspergillosis (>3 months)
Aspergillus
• Chronic cavitary pulmonary
• Aspergilloma of lung
• Chronic fibrosing pulmonary
• Chronic invasive sinusitis
Persistence • Maxillary (sinus) aspergilloma
without disease
- colonisation of
the airways or Allergic
nose/sinuses • Allergic bronchopulmonary (ABPA)
• Extrinsic allergic (broncho)alveolitis (EAA)
• Asthma with fungal sensitisation
• Allergic Aspergillus sinusitis (eosinophilic
fungal rhinosinusitis)
7.
Immunosuppression and infection
•Inhalation of aspergillus spores is a common
daily occurrence. A healthy immune system
would normally remove the spores and no
symptoms or infection would occur.
• In individuals whose immune system may be
suppressed either because of illness eg AIDS,
cancer patients or drugs, spores may germinate
and resulting tissue or systemic aspergillus
invasion can result.
• Individuals with allergies such as asthma, can
also be vulnerable to aspergillus disease.
8.
Interaction of Aspergilluswith the host
A unique microbial-host interaction
Frequency of aspergillosis
Frequency of aspergillosis
Acute IA
ABPA
Allergic sinusitis
Subacute IA
Tracheobronchitis
Aspergilloma
Chronic cavitary
Chronic fibrosing
Immune dysfunction Normal Immune hyperactivity
immune
function
. www.aspergillus.man.ac.uk
9.
Changing incidence offatal invasive
mycoses in non-HIV patients in USA
0.8
Rate per 100,000 population
0.2 0.4 0.6
Candidiasis
Aspergillosis
0.0
1981 1986 1991 1996
McNeil et al, Clin Infect Dis 2001;33:641
10.
Invasive pulmonary aspergillosis
IPA Normal lung
IPA occurs in ~7%
of acute leukaemia
patients, 10-15%
allogeneic BMT
patients
www.aspergillus.man.ac.uk
11.
Unequivocal ‘Halo sign’surrounding a nodule
Halo sign
Herbrecht, Denning et al, NEJM 2002;347:408-15.
Bleeding as anaspect of disseminated
invasive aspergillosis
Fumagillin is anti-angiogenic
A haemolysin described from
Aspergillus fumigatus
Other factors that
contribute to thrombosis or a
coagulopathy?
Gillies & Campbell, www.aspergillus.man.ac.uk
14.
How does Aspergillusfumigatus cause
thrombosis (clotting of vessels) and
also bleeding?
Interaction of
conidia and
endothelial cell Internalisation of
projections conidia (and hyphae)
by endothelial cells
with injury apparent
at 4 hours
Filler et al, Blood 2004;103:2134; Paris et al, Infect Immun 1997;65:1510.
15.
Cerebral aspergillosis (abscess)in
chronic lymphocytic leukaemia
Dissemination via
the blood stream to
the brain occurs in
~5% of cases of
invasive
aspergillosis, and in
~40% of allogeneic
bone marrow (HSCT)
recipients
www.aspergillus.man.ac.uk
16.
Early diagnosis ofinvasive aspergillosis
is important
Treatment started <10d >11d
Mortality 40% 90%
Von Eiff et al, Respiration 1995;62:241-7.
17.
Sputum Cultures forFungus
Bacteriological media inferior to
fungal media – 32% higher
yield on fungal media
A four day A. fumigatus culture on malt
extract agar (above). Light microscopy
pictures are taken at 1000x, stained with
lacto-phenol cotton blue.
18.
Aspergillus Antigen Test
•Diagnosis or surveillance?
• Only blood, or BAL, CSF etc
• Best OD cut-off - 0.7
• False positives in kids / antibiotics
• False negative with antifungal
prophylaxis
• Not as useful for non-hematology
• Not useful if pre-existing antibody
Herbrecht et al, J Clin Microbiol 2002;20:1898-906; and others
19.
Outcome from invasiveaspergillosis –
amphotericin B therapy
Survival Functions by Site of Infection
1.0
.9
.8
Sinusitis (n =17)
.7
.6
Multi-site (n =11)
.5
Aspe rgilloma (n =10)
.4
.3
.2 Pu lmonary (n =83)
.1
CNS o r Dissemin ated (n =35)
0.0
0 30 60 90 120 150 180 210 240 270 300 330 360
Days
Lin et al, Clin Infect Dis 2001;32:358
Sub-acute invasive aspergillosis
• Less immunocompromised patients
• Slower progression of disease (> 1 month)
• Cavitary or nodular pulmonary disease typical
• Vascular invasion less common
• Dissemination less common
• Antigen testing less useful
• Antibody testing may be helpful in diagnosis
www.aspergillus.man.ac.uk
22.
Chronic necrotizing aspergillosis
(CNPA)
Chronic necrotizing pulmonary aspergillosis
(CNPA) is a subacute process usually found in
patients with some degree of
immunosuppression.
Usually it is associated with underlying lung
disease, alcoholism, or chronic corticosteroid
therapy. Because it is uncommon, CNPA often
remains unrecognized for weeks or months and
causes a progressive cavitary pulmonary
infiltrate.
23.
Chronic necrotising pulmonaryaspergillosis
Right upper lobe showing circular
Right lobe shows huge cavity
shadow partly filled by a mass. PT MS
containing some debris, with
1996
+ve aspergillus precipitins.Pt
MS 1999
Right upper lobe. Patient has Same lobe shows expansion of
diabetes and pulmonary the shadow, still partially filled
mycobacterium avium- shows small with a mass. Pt MS 1998
cavitary lesion PT MS 1995.
Denning, Clin Microbiol Infect 2001;7(Suppl 2):25-31.
24.
CLASSIFICATION OF ASPERGILLOSIS
Invasive aspergillosis
• Acute (<1 month course)
Airways/nasal • Subacute/chronic necrotising (1-3 months)
exposure to
airborne Chronic aspergillosis (>3 months)
Aspergillus
• Chronic cavitary pulmonary
• Aspergilloma of lung
• Chronic fibrosing pulmonary
• Chronic invasive sinusitis
Persistence • Maxillary (sinus) aspergilloma
without disease
- colonisation of
the airways or Allergic
nose/sinuses • Allergic bronchopulmonary (ABPA)
• Extrinsic allergic (broncho)alveolitis (EAA)
• Asthma with fungal sensitisation
• Allergic Aspergillus sinusitis (eosinophilic
fungal rhinosinusitis)
25.
Aspergillus and airways
Typesof aspergillosis of the airways
• Colonisation (no disease – could be at risk)
• Obstructing Aspergillus tracheobronchitis /Mucus
impaction (non-invasive)
• Aspergillus bronchitis/tracheobronchitis
(superficially invasive only)
• Ulcerative Aspergillus tracheobroncitis (locally
invasive) (lung transplants – at anastomosis)
• Pseudomembranous Aspergillus tracheobronchitis
(Extensive disease, locally invasive, associated with
IPA and may disseminate)
Langley, ATS 2004
Chronic pulmonary aspergillosis-
serology
All 18 patients had positive Aspergillus precipitins
(1+ - 4+)
All 18 patients had elevated inflammatory
markers, CRP, PV and / or ESR
14 of 18 (78%) had elevated total IgE (>20), 13
>200 and 7 >400
9 of 14 (67%) had Aspergillus specific IgE (RAST)
Denning DW et al, Clin Infect Dis 2003; 37:S265
32.
Chronic cavitary pulmonaryaspergillosis
(CCPA)
Patient RW
Patient RW September 1992
December 1991 Relapse in normal lung
Pre surgical resection
www.aspergillus.man.ac.uk
Chronic cavitary pulmonaryaspergillosis
Patient JP
June 1999
Denning DW et al, Clin Infect Dis 2003; 37:S265
39.
Chronic Cavitary PulmonaryAspergillosis, with
aspergilloma
Patient JP
July 2001
Denning DW et al, Clin Infect Dis 2003; 37:S265
40.
Chronic Fibrosing PulmonaryAspergillosis
Patient JP
April 2002
Denning DW et al, Clin Infect Dis 2003; 37:S265
41.
Mannose Binding Lectin(MBL)- a key part
of the innate immune system
Di b
il dn
sh o
u ed
p
I ri w
nt i
tc t
eo h
an
cc e o
oi c r
l tr p
l n t
e e
E
x
on
1
I ri w
nt i
tc t
eo h
an
MA
SP
E
x
on
2
C
R
D
E
x
on
3 2n t
+ ne
C di
aii s
bg
E
x
on
4
Crosdale et al J Infect Dis 2001;184:653
42.
Mannose Binding Protein
Mutations
5 mutations described
2 in promoter region (less important)
3 in open reading frame (M52, M54, M57)
Codon 54 mutation present in 16% of Caucasian
homozygous in 2%
Defects associated with bacterial infections in
children and hepatitis B carriage
Eisen & Minchinton Clin Infect Dis 2003;37:1496
43.
CCPA and humangene defects
• 8 of 11 (72%) had low MBL genotypes p=<0.05
(compared to normal controls)
• 8 of 17 (47%) had low MBL genotypes p=0.0002
• 32% and 21.5% frequency of 2 SPA2 mutations,
compared with normals (18% and 11%) (p=0.021
and p=0.044)
• not related to coeliac disease (<1 in 30)
Crosdale et al J Infect Dis 2001;184:653; Vaid et al, unpublished.
44.
CLASSIFICATION OF ASPERGILLOSIS
Invasive aspergillosis
• Acute (<1 month course)
Airways/nasal • Subacute/chronic necrotising (1-3 months)
exposure to
airborne Chronic aspergillosis (>3 months)
Aspergillus
• Chronic cavitary pulmonary
• Aspergilloma of lung
• Chronic fibrosing pulmonary
• Chronic invasive sinusitis
Persistence • Maxillary (sinus) aspergilloma
without disease
- colonisation of
the airways or Allergic
nose/sinuses • Allergic bronchopulmonary (ABPA)
• Extrinsic allergic (broncho)alveolitis (EAA)
• Asthma with fungal sensitisation
• Allergic Aspergillus sinusitis (eosinophilic
fungal rhinosinusitis)
45.
ALLERGIC BRONCHOPULMONARY
ASPERGILLOSIS – Key diagnostic criteria
ABPA possible
• Asthma
ABPA possible
• Blood eosinophilia (>1,000 / cu mm)
ABPA probable
• History of pulmonary infiltrates
ABPA almost certain
• Central bronchiectasis
• Precipitins against A. fumigatus positive If 3 tests +ve,
• Aspergillus IgE antibody >2x asthma control then ABPA very
• Aspergillus IgG antibody >2x asthma control likely,
If all 4 +ve the
• Total serum IgE concentration, >1000 iu/mL diagnosis
established
Rickett et al. Arch Intern Med 1983; 143: 1553; Patterson, Chest 2000;118:7
46.
ABPA
After bronchoscopy
Before bronchoscopy
www.aspergillus.man.ac.uk
ABPA - CTshowing central bronchiectasis
www.aspergillus.man.ac.uk
49.
ABPA and surfactant
5surfactant proteins in man, SPA1, SPA2, SPB, SPC and SPD
– all ‘collectin’ family
Mason et al, Am J Physiol 1998;275:L1-13.
50.
ABPA – surfactantdefects
2 exonic polymorphisms, and 2 intronic polymorphisms in SP-
A2 associated with ABPA
A1660G = OR of 4.78; or if combined with G1649C = OR 10.4
Also associated with higher peripheral eosinophilia
Saxena et al, J Allergy Clin Immunol 2003;111:1001-7.
51.
Eosinophilic fungal rhinosinusitis
or allergic fungal sinusitis
Patient with chronic symptoms
of nasal obstruction, loss of smell
and nasal polyps
Ponikau et al, Mayo Clinic Proc 1999;74:877 & WWW.aspergillus.man.ac.uk
52.
Eosinophilic fungal rhinosinusitis
(linkwith airborne fungi - ?which most important
= Myelin basic protein, highly toxic to local epithelium
Ponikau et al, Mayo Clinic Proc 1999;74:877
Fungal-associated asthma –evidence
Severe asthma linked
with fungal
sensitisation
Frequency of fungal
sensitisation
ABPA Fungal-associated
asthma
Treatment of ABPA High spore counts and
and pilot data asthmatic attacks
55.
Spore counts andasthma attacks and
admission to hospital
All circumstantial evidence
• Thunderstorm asthma – linked to Alternaria
• Asthma deaths (Chicago) linked to high
ambient spores counts and season (summer
autumn) when spore counts highest
• Asthma hospital admission linked to high
ambient spore counts (Derby, New Orleans,
Ottawa
• Asthma hospital attendance linked to high
spore counts , but not pollen counts (Canada)
• Asthma symptoms increased on days of high
spore counts (California, Pennsylvania)
O'Hollaren, N Engl J Med 1991; 324: 359; Newson, Occup Environ Med 2000; 57: 786-92.
56.
Fungus at home
Environmentaldata
• Mouldy housing associated with worse
asthma, with a correlation between asthma
severity and degree of dampness in the
home and separately with visible mould
growth
• In Germany bronchial reactivity in children
was associated with damp housing
• Mouldy and damp school associated with
asthma symptoms and emergency room visits
• Highest concentration of Aspergillus
fumigatus is at home
Williamson, Thorax 1997;52:229. Taskinen, Acta Paediatr 1999; 88:1373.
57.
Mild asthma –564 (50%)
Moderate asthma – 333 (29%)
Severe asthma and moulds
Severe asthma – 235 (21%) – linked with
fungus skin test positivity
Zureik et al, Br Med J 2002;325:411
58.
Asthma severity, housedust mites, cats
and moulds
Allergen No asthma Mild asthma Moderate Severe
n= 111 FEV1 >75% asthma FEV1 asthma FEV1
<90% >60% <75% >60%
n= 67 n= 42 n= 42
House dust 61% 71% 45% 77%
mite
Cats* 49% 51% 38% 35%
Moulds# 17% 19% 36% 31%
* P = 0.05
# p = 0.01
Langley, ATS 2004